KR102729973B1 - 인플루엔자 헤마글루티닌에 대한 인간 항체 - Google Patents

인플루엔자 헤마글루티닌에 대한 인간 항체 Download PDF

Info

Publication number
KR102729973B1
KR102729973B1 KR1020177020050A KR20177020050A KR102729973B1 KR 102729973 B1 KR102729973 B1 KR 102729973B1 KR 1020177020050 A KR1020177020050 A KR 1020177020050A KR 20177020050 A KR20177020050 A KR 20177020050A KR 102729973 B1 KR102729973 B1 KR 102729973B1
Authority
KR
South Korea
Prior art keywords
antibody
influenza
antigen
antibodies
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177020050A
Other languages
English (en)
Korean (ko)
Other versions
KR20170098888A (ko
Inventor
리사 에이. 퍼셀
조나단 비아우
윌리엄 올슨
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20170098888A publication Critical patent/KR20170098888A/ko
Application granted granted Critical
Publication of KR102729973B1 publication Critical patent/KR102729973B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C07K16/1018—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177020050A 2014-12-19 2015-12-18 인플루엔자 헤마글루티닌에 대한 인간 항체 Active KR102729973B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462094752P 2014-12-19 2014-12-19
US62/094,752 2014-12-19
US201562152122P 2015-04-24 2015-04-24
US62/152,122 2015-04-24
PCT/US2015/066654 WO2016100807A2 (en) 2014-12-19 2015-12-18 Human antibodies to influenza hemagglutinin

Publications (2)

Publication Number Publication Date
KR20170098888A KR20170098888A (ko) 2017-08-30
KR102729973B1 true KR102729973B1 (ko) 2024-11-14

Family

ID=55073153

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177020050A Active KR102729973B1 (ko) 2014-12-19 2015-12-18 인플루엔자 헤마글루티닌에 대한 인간 항체

Country Status (19)

Country Link
US (3) US10392432B2 (enExample)
EP (1) EP3233908A2 (enExample)
JP (2) JP6711828B2 (enExample)
KR (1) KR102729973B1 (enExample)
CN (1) CN108064240B (enExample)
AU (1) AU2015364415B2 (enExample)
BR (1) BR112017012944A2 (enExample)
CA (1) CA2969749A1 (enExample)
CL (2) CL2017001610A1 (enExample)
CO (1) CO2017006580A2 (enExample)
EA (1) EA036953B1 (enExample)
IL (1) IL252659B (enExample)
MX (2) MX386403B (enExample)
MY (1) MY185320A (enExample)
PH (1) PH12017500949A1 (enExample)
SG (2) SG10202010170SA (enExample)
TW (2) TWI701258B (enExample)
UY (1) UY36458A (enExample)
WO (1) WO2016100807A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA3015347A1 (en) 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
EP3515491A4 (en) 2016-09-21 2020-09-16 Aptevo Research and Development LLC CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND PROCESSES
US11667697B2 (en) 2016-10-19 2023-06-06 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor
TW202311284A (zh) * 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體
WO2019006162A1 (en) 2017-06-28 2019-01-03 Bluefin Biomedicine, Inc. ANTI-LY6H ANTIBODIES AND CONJUGATES ANTIBODY-MEDICINE
MX2020001879A (es) * 2017-08-18 2020-07-29 Gritstone Oncology Inc Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
EP3638698B1 (en) * 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments
SG11202006379UA (en) 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin
EP3758749A4 (en) 2018-03-02 2022-07-06 The University of Chicago METHOD AND COMPOSITION FOR NEUTRALIZING INFLUENZA
KR20200060969A (ko) * 2018-11-23 2020-06-02 (주)셀트리온 인플루엔자 바이러스 질환을 치료하기 위한 투여 요법
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
EP3946613A1 (en) * 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
EP3945800A1 (en) 2019-04-03 2022-02-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for insertion of antibody coding sequences into a safe harbor locus
JP7634231B2 (ja) 2019-05-31 2025-02-21 ワシントン ユニバーシティ Ｐａｎ－ノイラミニダーゼ阻害抗体
US20220298230A1 (en) * 2019-06-11 2022-09-22 The Rockefeller University Antibodies and methods for treatment of viral infections
EP4010021A4 (en) * 2019-08-06 2023-08-30 Regents of the University of Minnesota COMPOSITIONS AND METHODS FOR TREATING SERPINE B13 DISORDERS
JP7611908B2 (ja) * 2019-10-28 2025-01-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗血球凝集素抗体およびその使用方法
MX2022008901A (es) * 2020-01-24 2022-08-16 Regeneron Pharma Conjugados de proteinas-compuestos antivirales.
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
AU2021219671A1 (en) * 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
US20230122364A1 (en) * 2020-03-27 2023-04-20 Vanderbilt University HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CN117050175B (zh) * 2020-04-17 2024-07-16 珠海泰诺麦博制药股份有限公司 抗人神经生长因子的抗体
BR112022021780A2 (pt) 2020-04-27 2023-03-07 Twist Bioscience Corp Bibliotecas de ácido nucléico variantes para coronavírus
WO2022082030A2 (en) 2020-10-15 2022-04-21 Gritstone Bio, Inc. Antigen-binding proteins and related methods of use
US20230391856A1 (en) * 2020-10-23 2023-12-07 Icahn School Of Medicine At Mount Sinai Sars-cov-2 antibodies and uses thereof
KR20230135569A (ko) * 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
WO2022155503A1 (en) 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
KR102604669B1 (ko) * 2021-03-30 2023-11-21 충남대학교산학협력단 조류인플루엔자 바이러스의 ha 단백질에 특이적인 단클론항체, 및 이의 용도
KR20240038928A (ko) 2021-07-28 2024-03-26 리제너론 파마슈티칼스 인코포레이티드 단백질-항바이러스 화합물 접합체
EP4396235A4 (en) * 2021-09-02 2025-07-02 Memorial Sloan Kettering Cancer Center ANTI-CD33 ANTIBODIES AND THEIR USES
US20250059260A1 (en) * 2021-12-22 2025-02-20 The University Of Chicago Methods for detecting or treating influenza infections
MX2024008361A (es) 2022-01-14 2024-09-10 Regeneron Pharma Derivados de verrucarina a y conjugados anticuerpo-fármaco de los mismos.
EP4626553A2 (en) 2022-11-30 2025-10-08 Regeneron Pharmaceuticals, Inc. Tlr7 agonists and antibody-drug-conjugates thereof
CN115993452B (zh) * 2023-03-23 2023-06-16 深圳市卫光生物制品股份有限公司 一种流感病毒疫苗血凝素含量测定方法及试剂盒
EP4791784A1 (en) * 2023-10-13 2026-08-19 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-ny-eso-1 antibodies and uses thereof
WO2025117727A1 (en) 2023-11-29 2025-06-05 Regeneron Pharmaceuticals, Inc. Analogs of quinoxaline/quinoline cytotoxins, linker- payloads, protein-drug conjugates, and uses thereof
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025166216A1 (en) * 2024-02-02 2025-08-07 The Board Of Regents Of The University Of Texas System Trop2-targeting antibodies and uses thereof
WO2025184137A1 (en) * 2024-02-27 2025-09-04 Adimab, Llc Influenza antibodies and methods of use thereof
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025255258A2 (en) * 2024-06-05 2025-12-11 Vaxart, Inc. Antibodies targeting gii genotypes of human norovirus

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013011347A1 (en) * 2011-07-18 2013-01-24 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589174A (en) 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
CA2663388C (en) 2006-09-07 2017-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
CN102046654A (zh) 2007-03-13 2011-05-04 胡马斯有限公司 针对甲型流感病毒h5n1株系的抗体
JP5597128B2 (ja) 2007-05-11 2014-10-01 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５トリインフルエンザの診断および監視に有用なｈ５亜型特異的結合タンパク質
CN103254308B (zh) 2007-06-15 2015-01-21 厦门大学 H5亚型禽流感病毒血凝素蛋白的单克隆抗体或其结合活性片段及其用途
US8383121B2 (en) 2007-09-13 2013-02-26 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
JP5490695B2 (ja) 2007-09-13 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
EP3524619A1 (en) 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
JP5490725B2 (ja) 2008-02-05 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド Ｈ５亜型インフルエンザウイルスの普遍的な検出のための結合タンパク質およびエピトープブロッキングｅｌｉｓａ
WO2009111865A1 (en) 2008-03-12 2009-09-17 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health Reagents and methods for detecting influenza virus proteins
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
CA2719201A1 (en) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc. Neutralizing molecules to viral antigens
CN101990575B (zh) 2008-03-28 2015-06-17 国立大学法人北海道大学 抗h5亚型a型流感病毒血凝素单克隆抗体
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
CA2731686C (en) 2008-07-25 2020-04-07 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US20120128684A1 (en) 2008-08-25 2012-05-24 Burnham Institute For Medical Research Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
US8894997B2 (en) 2009-04-30 2014-11-25 Vanderbilt University Monoclonal antibodies to influenza H1N1 virus uses thereof
KR101790354B1 (ko) 2009-05-11 2017-10-25 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 바이러스 ｈ3ｎ2를 중화시킬 수 있는 인간 결합 분자 및 그것의 용도
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
EP2464383A4 (en) 2009-08-14 2013-02-13 Theraclone Sciences Inc COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF GRIP
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
CN102791734B (zh) 2010-03-08 2014-10-15 赛特瑞恩股份有限公司 源自人b细胞且具有抗甲型流感病毒的中和活性的人单克隆抗体
HRP20170490T1 (hr) 2010-03-26 2017-06-02 Pomona Ricerca S.R.L. Imunoglobulini pune dužine igg izotipa sposobni za prepoznavanje heterosubtipnog epitopa neutralizacije na području stabljike hemaglutinina i njihova uporaba kao lijek protiv gripe
RU2635999C2 (ru) 2010-06-17 2017-11-17 ТРЕЛЛИС БАЙОСАЙЕНС, ЭлЭлСи Антитела, подходящие для пассивной иммунизации против гриппа
EP2603237A4 (en) 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
JP6101204B2 (ja) 2010-08-23 2017-03-22 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザｈ５赤血球凝集素の主要中和エピトープに特異的なモノクローナル抗体
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (en) 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor
US8900585B2 (en) 2010-10-20 2014-12-02 New York Blood Center, Inc. Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection
AU2012217867A1 (en) 2011-02-14 2013-09-05 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
WO2013081463A2 (en) 2011-12-02 2013-06-06 Aimm Therapeutics B.V. Influenza a virus specific antibodies
MX360056B (es) 2012-03-08 2018-10-19 Janssen Vaccines & Prevention Bv Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
AU2013260123A1 (en) 2012-05-10 2014-11-13 Massachusetts Institute Of Technology Agents for influenza neutralization
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US20140086927A1 (en) 2012-09-25 2014-03-27 Fujita Health University Novel epitope and mechanism of antigen-antibody interaction in an influenza virus
BR112015010817A8 (pt) * 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
SG11201602522VA (en) 2013-10-02 2016-04-28 Medimmune Llc Neutralizing anti-influenza a antibodies and uses thereof
TWI701258B (zh) 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3638698B1 (en) * 2018-01-26 2021-03-03 Regeneron Pharmaceuticals, Inc. Anti-tmprss2 antibodies and antigen-binding fragments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013011347A1 (en) * 2011-07-18 2013-01-24 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Also Published As

Publication number Publication date
WO2016100807A3 (en) 2016-08-04
EA036953B1 (ru) 2021-01-19
MX2017008186A (es) 2018-02-09
CO2017006580A2 (es) 2017-09-29
CL2017001610A1 (es) 2018-03-09
TW201632548A (zh) 2016-09-16
MX2021007679A (es) 2021-08-05
CN108064240B (zh) 2022-01-04
IL252659B (en) 2021-06-30
EA201791086A1 (ru) 2018-01-31
AU2015364415B2 (en) 2021-09-02
US10392432B2 (en) 2019-08-27
JP6711828B2 (ja) 2020-06-17
SG11201704212SA (en) 2017-06-29
JP2018503361A (ja) 2018-02-08
US20200017576A1 (en) 2020-01-16
US20200377575A1 (en) 2020-12-03
BR112017012944A2 (pt) 2018-05-15
MY185320A (en) 2021-05-04
US10689436B2 (en) 2020-06-23
TWI701258B (zh) 2020-08-11
US11453714B2 (en) 2022-09-27
TW202026310A (zh) 2020-07-16
AU2015364415A1 (en) 2017-06-15
CL2019002196A1 (es) 2019-12-13
MX386403B (es) 2025-03-04
TWI702229B (zh) 2020-08-21
US20160176953A1 (en) 2016-06-23
PH12017500949A1 (en) 2017-10-02
CN108064240A (zh) 2018-05-22
WO2016100807A2 (en) 2016-06-23
SG10202010170SA (en) 2020-11-27
EP3233908A2 (en) 2017-10-25
CA2969749A1 (en) 2016-06-23
UY36458A (es) 2016-07-29
IL252659A0 (en) 2017-07-31
KR20170098888A (ko) 2017-08-30
JP2019055996A (ja) 2019-04-11

Similar Documents

Publication Publication Date Title
CN108064240B (zh) 针对流感血凝素的人抗体
JP7500812B2 (ja) 中東呼吸器症候群－コロナウイルススパイクタンパク質に対するヒト抗体
CN113354732B (zh) 针对埃博拉病毒糖蛋白的人抗体
JP2022130593A (ja) 抗アクチビンａ抗体及びその使用
KR102820941B1 (ko) 인플루엔자 헤마글루티닌에 대한 인간 항체
JP7611908B2 (ja) 抗血球凝集素抗体およびその使用方法
EA046393B1 (ru) Антитела к гемагглютинину и их применение
EA044791B1 (ru) Человеческие антитела к гемагглютинину вируса гриппа

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PA0102 Application to register extension of term of patent right following delayed registration

St.27 status event code: A-4-4-G10-G15-tad-PA0102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 46

PR1102 Extension of patent period due to registration delay

St.27 status event code: A-4-4-G10-G17-tad-PR1102

Protection beyond ip right term event data comment text: Claim Total Quantity : 0, Period Limitation Text : 46

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000